Navigation Links
Fuisz Pharma Announces Novel Anti Abuse System for Opiates
Date:1/27/2010

MIAMI and LJUBLJANA, Slovenia, Jan. 27 /PRNewswire/ -- Fuisz Pharma today announced the development of a novel anti-abuse system intended for use with abuse prone drugs. This system seeks to address the misuse of addictive drugs with a particular emphasis on opiates and is applicable to all dosage forms.

Fuisz Pharma President, Joseph Matus Fuisz commented: "The desirability of an effective anti abuse system is well understood. The United States Government has estimated that thirty six million Americans will abuse a medication at some point in their lifetime. Abuse is particularly prevalent in the pain area. Notwithstanding this need, the industry has found it challenging to implement abuse resistant dosage forms despite Herculean formulation efforts. This is due primarily to the fundamental tension between the bioavailability of a drug in the body and the prevention of extraction from the dosage form and other types of misuse by a highly motivated and sophisticated population of abusers."

Mr. Fuisz continued: "The Fuisz system for preventing abuse combines, as the best inventions do, novelty with simplicity. We are confident that our anti-abuse system will be welcomed by our pharmaceutical partners as well as by those concerned with drug misuse issues and the public and private health practitioner."

Noted pharmaceutical inventor Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz) was one of the inventors of the methodology.

Fuisz Pharma is a private pharmaceutical company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery (orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, etc.) and have extensive experience working with big and specialty pharma. Fuisz Pharma has offices in Miami and Los Angeles as well as a presence in the EU through Ljubljana, Slovenia.

SOURCE Fuisz Pharma


'/>"/>
SOURCE Fuisz Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
2. Pharma CI Conference Amy Yueh Pays $52,000 to Apaporis LLC to Satisfy Judgment Against Her In Superior Court Of New Jersey Case
3. Steven Leventer Joins PharmaNet Development Group as Vice President, Clinical Research Neuroscience
4. Intercept Pharmaceuticals Raises $25 Million Series B Financing
5. Pharma Billionaire Stewart Rahr Provides Substantial Donation to Haiti Charities
6. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
7. Amylin Pharmaceuticals to Webcast Year-End Financial Results
8. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
9. New Life Agency, Inc. Joins Forces With The Diamond Institute and Walgreens Specialty Pharmacy to Introduce the Nations First In Vitro Fertilization Insurance Program
10. New White Paper Examines Advanced Mycoplasma Tests - How Real-Time PCR Analysis Helps Save Time and Money for Biopharmaceutical Manufacturers
11. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... president, effective Aug. 7, 2017. ... other interests and will serve as president emeritus during a ... us in multiple leadership roles since he joined Diplomat with ... has provided decisive, strategic leadership which continues to benefit our ...
(Date:8/3/2017)... Aug. 3, 2017  Opioid addiction and other drugs ... healthcare costs and threatening outcomes, were problems taken on ... IVD industry that support them, met this week. This ... said that drugs of abuse, procalcitonin and acute kidney ... the organization,s 69th meeting in San Diego, ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... An August 3rd article on Reuters covers ... of a report in JAMA (the Journal of the American Medical Association). The study found ... to achieve BMIs under 30, when compared to patients with lower BMIs. At present, weight ...
(Date:8/16/2017)... GA (PRWEB) , ... August 16, 2017 , ... ... new Inc. 5000. The company ranked #4429 on the newly released, 36th annual ... list represents a unique look at the most successful companies within the American economy’s ...
(Date:8/16/2017)... Brentwood, TN (PRWEB) , ... August 16, 2017 ... ... market-leading dermatology practice partnerships through affiliations and de novo development, today announced ... practice. , Cumberland Skin Surgery and Dermatology, with offices in both Hermitage ...
(Date:8/16/2017)... ... 16, 2017 , ... Paul Vitenas, MD, FACS , is honored to ... annual list identifies the nation’s top physicians, in a variety of specialties. This marks ... top of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider ...
(Date:8/16/2017)... ... August 16, 2017 , ... SGNA Standards of Infection Control ... cycle, both between patient procedures and before storage, is a requisite practice crucial ... to the prevention of disease transmission and nosocomial infection as cleaning and HLD.” ...
Breaking Medicine News(10 mins):